You are leaving Medscape Education

Cancel Continue

CME & Education

Clinical Advances in

Quality Improvement of Type 2 Diabetes: Improving Patient Outcomes

Glycemic control remains the cornerstone of management of type 2 diabetes (T2D) as it plays a vital role in preventing or delaying the onset and progression of complications. Individualizing therapeutic goals and using modern antihyperglycemic agents when appropriate is crucial to safe and effective management of T2D. These educational activities aim to increase awareness of cardiovascular outcomes data and provide practical strategies to help patients achieve T2D goals using combination therapy.

CME Activities

Quality Focused T2D Management

Clinical Application of Modern T2D Agents

Conference Coverage

Polling Question

Related Resources

Downloadable Slide Kit

Cardiovascular Outcome Trials and Real-World Data

Review recently published CV outcome trial data on antihyperglycemic agents, including real-world data on SGLT2 inhibitors.

Clinical Articles

ADA Standards of Medical Care in Diabetes, 2017

AACE/ACE Comprehensive Diabetes Management Algorithm, 2017

Position Statement of the ADA and the EASD, 2015

Patient Resources

Type 2 Diabetes: Treatment Changes Over Time

Related Links

The NCQA State of Health Care Quality Report

NCQA HEDIS Physician Measures, 2015

AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk, 2013

ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, 2013

NLA Recommendations for Patient- Centered Management of Dyslipidemia, 2014

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, 2015

AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults, 2013

Evidence-based Guideline for the Management of High Blood Pressure in Adults, JNC 8

ASH/ISH Clinical Practice Guidelines for the Management of Hypertension, 2014

ESH/ESC Guidelines for the Management of Arterial Hypertension, 2013

Steering Committee

Anne L. Peters, MD

Steering Committee Chair

Professor, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California, Los Angeles, California

John E. Anderson, MD

The Frist Clinic, Nashville, Tennessee

Lawrence Blonde, MD

Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana

Daniel Einhorn, MD

Clinical Professor, University of California at San Diego; Medical Director, Scripps Whittier Diabetes Institute, La Jolla, California

Julio Rosenstock, MD

Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas

Carol H. Wysham, MD

Clinical Professor of Medicine, University of Washington, Spokane, Washington

Steering Committee

Anne L. Peters, MD

Steering Committee Chair

has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Bigfoot Biomedical; Biodel; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CVS Caremark; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Optum Rx; Thermalin

Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals; Lilly

Received grants for clinical research from: Janssen Pharmaceuticals

John E. Anderson, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Sanofi

Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Sanofi

Lawrence Blonde, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Quest Diagnostics; Sanofi

Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Sanofi

Received grants for clinical research from: Lexicon Pharmaceuticals, Inc.; Lilly; Novo Nordisk; Sanofi

Daniel Einhorn, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Halozyme Therapeutics; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi

Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Received grants for clinical research from: Halozyme Therapeutics; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.

Owns stock, stock options, or bonds from: Halozyme Therapeutics

Julio Rosenstock, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk; Sanofi

Received grants for clinical research from: Asahi; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; GlaxoSmithKline; Hanmi Pharmaceuticals; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Lilly; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi; Takeda Pharmaceuticals North America, Inc.

Carol H. Wysham, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Sanofi

Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Novo Nordisk; Sanofi

Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Novo Nordisk; Sanofi